Shanghai Fosun Pharma’s FCN-159 Receives Priority Review for Pediatric Neurofibromatosis Treatment
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has achieved a significant milestone...
Drug
Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it...
Gilead’s Seladelpar Shows Interim Benefits in PBC-Related Itch Clinical Trial
Gilead Sciences (NASDAQ: GILD) has announced interim results from a long-term study assessing the safety...
BMS’s Sotyktu Sustains Clinical Response in Long-Term Psoriasis Treatment
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the release of long-term clinical data for...
Jiangsu Hengrui’s SHR1905 Anti-TSLP mAb Gets Green Light for COPD Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, announced that it...
Innovent Biologics’ IBI311 New Drug Application Accepted for Review by China’s CDE
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
Zai Lab and Innoviva Win China Approval for SUL-DUR to Treat Hospital-Acquired Pneumonia
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, in collaboration with US...
FDA Gives Accelerated Nod to Amgen’s Imdelltra in Small Cell Lung Cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to Amgen (NASDAQ: AMGN)...
Eli Lilly’s Weekly Insulin Efsitora Alfa Matches Daily Basal Insulins in Reducing A1C Levels
Eli Lilly and Company (NYSE: LLY), a global healthcare company, has announced results from a...
Biotherus Inc. Advances PM8002 Bispecific Antibody to Phase III for Triple Negative Breast Cancer
China’s Biotheus Inc. has announced the initiation of a Phase III clinical study for its...
Jiangsu Hengrui’s Camrelizumab/Apatinib Combo Denied FDA Approval Over Manufacturing Issues
The US Food and Drug Administration (FDA) has issued a complete response letter to Jiangsu...
ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...
CSPC Pharmaceutical’s βKlotho Monoclonal Antibody JMT202 Receives Clinical Trial Approval from NMPA
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Roche’s CT-388 Shows Significant Weight Loss in Phase I Clinical Trial for Obesity
Switzerland-based healthcare giant Roche (SWX: ROG) has announced preliminary results from a Phase I study...
Eisai to Support Grassroots Healthcare in China with Significant Pariet Donation
Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000...
North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China
North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...
HutchMed’s Sovleplenib Phase III Results to be Showcased at EHA 2024
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013), a biopharmaceutical company based in China, is preparing...
Shanghai UniCAR-Therapy’s Innovative CAR-T Therapy Targets Breakthrough Designation with IL-6 Silencing
Shanghai UniCAR-Therapy Bio-Medicine Technology Co., Ltd, a leading biopharmaceutical company based in China, is on...
Bayer’s 225Ac-PSMA-Trillium Therapy Begins Early-Stage Clinical Trial for mCRPC
Bayer AG (ETR: BAYN), a multinational pharmaceutical company based in Germany, has this week commenced...
Roc Rock Biotechnology Secures Ethical Approval for CAR-M Therapy in Ovarian Cancer
China-based Roc Rock Biotechnology Co., Ltd. has announced that it has received ethical approval from...